Ahmer Hameed , Katie Connor , Alan Timpson , Lora Irvine , Sharon Zahra , Caroline Fattah , Kirsty Duncan , John Plevris , Chris Fraser , Avinash Sewpaul , Shareen Forbes , John Casey , Andrew Sutherland
{"title":"Islet cell alloautotransplantation 12 years after simultaneous pancreas-kidney transplantation","authors":"Ahmer Hameed , Katie Connor , Alan Timpson , Lora Irvine , Sharon Zahra , Caroline Fattah , Kirsty Duncan , John Plevris , Chris Fraser , Avinash Sewpaul , Shareen Forbes , John Casey , Andrew Sutherland","doi":"10.1016/j.ajt.2025.05.034","DOIUrl":null,"url":null,"abstract":"<div><div><span>Late enteric bleeding in the setting of simultaneous pancreas-kidney transplantation is an uncommon but perhaps underrecognized complication that can result in major morbidity. There are significant challenges both in the diagnosis and management of this complication, and in certain circumstances, graft pancreatectomy<span> of an otherwise functioning graft may be required. Here we present the case of a 49-year-old simultaneous pancreas-kidney transplant recipient who presented 12 years after transplant with recurrent life-threatening enteric bleeding that required a graft pancreatectomy. After pancreatectomy, islets were isolated from the allograft—190 000 islet equivalents with 90% viability and 27% purity. The islets were transplanted back into the recipient percutaneously via the portal vein<span>, with detectable C-peptide 6 weeks after procedure and no hypoglycemic unawareness. A second allogeneic islet cell transplant was subsequently performed two months later, with the patient’s latest C-peptide of 430 pmol/L, having maintained good renal function. Alloautotransplantation is a potential treatment option for patients that require graft pancreatectomy and has the advantage of preserving some beta-cell function while not necessitating additional </span></span></span>immunosuppression.</div></div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 10","pages":"Pages 2244-2248"},"PeriodicalIF":8.2000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Transplantation","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1600613525002916","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
Abstract
Late enteric bleeding in the setting of simultaneous pancreas-kidney transplantation is an uncommon but perhaps underrecognized complication that can result in major morbidity. There are significant challenges both in the diagnosis and management of this complication, and in certain circumstances, graft pancreatectomy of an otherwise functioning graft may be required. Here we present the case of a 49-year-old simultaneous pancreas-kidney transplant recipient who presented 12 years after transplant with recurrent life-threatening enteric bleeding that required a graft pancreatectomy. After pancreatectomy, islets were isolated from the allograft—190 000 islet equivalents with 90% viability and 27% purity. The islets were transplanted back into the recipient percutaneously via the portal vein, with detectable C-peptide 6 weeks after procedure and no hypoglycemic unawareness. A second allogeneic islet cell transplant was subsequently performed two months later, with the patient’s latest C-peptide of 430 pmol/L, having maintained good renal function. Alloautotransplantation is a potential treatment option for patients that require graft pancreatectomy and has the advantage of preserving some beta-cell function while not necessitating additional immunosuppression.
期刊介绍:
The American Journal of Transplantation is a leading journal in the field of transplantation. It serves as a forum for debate and reassessment, an agent of change, and a major platform for promoting understanding, improving results, and advancing science. Published monthly, it provides an essential resource for researchers and clinicians worldwide.
The journal publishes original articles, case reports, invited reviews, letters to the editor, critical reviews, news features, consensus documents, and guidelines over 12 issues a year. It covers all major subject areas in transplantation, including thoracic (heart, lung), abdominal (kidney, liver, pancreas, islets), tissue and stem cell transplantation, organ and tissue donation and preservation, tissue injury, repair, inflammation, and aging, histocompatibility, drugs and pharmacology, graft survival, and prevention of graft dysfunction and failure. It also explores ethical and social issues in the field.